好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Motor Network Neurophysiological (TMS-EEG) Markers as Predictors of Long-term Outcomes Following Ventriculoperitoneal Shunt in Normal Pressure Hydrocephalus
Movement Disorders
P10 - Poster Session 10 (8:00 AM-9:00 AM)
16-001
This study evaluated whether a TMS-evoked potential (TEP)-based test, Delphi-MD, can predict long-term (over one year) response to VPS as an ancillary tool to improve decision-making.

Current approaches for normal pressure hydrocephalus (NPH) depend on clinical assessment, imaging, and procedures like CSF tap tests to guide ventriculoperitoneal shunt (VPS) decisions. 

Forty-one patients with possible iNPH underwent Delphi-MD evaluation of wave form adherence (WFA), a composite measure assessing how closely their TEPs resembled an ideal benchmark TEP. Eighteen patients received VPS based on multidisciplinary team decision. Response was assessed over >1 year using the clinical global impression of change (CGIC), along with the 10-meter timed up and go test and the modified Rankin scale.

Responders showed higher baseline left primary motor cortex (M1L) WFA values than non-responders (median 0.51 [95% CI 0.36–0.76] vs. 0.14 [95% CI -0.02–0.38], p=0.012). Furthermore, M1L WFA effectively distinguished responders (11/18) from non-responders (7/18), with an ROC-AUC of 0.935 (bootstrap 95% CI 0.792–1.00, p<0.0001). The cutoff, validated via leave-one-out cross-validation, yielded 90.9% sensitivity, 85.7% specificity, and 88.9% accuracy. CSF tap tests, in contrast, did not predict responsiveness.

This study indicates that higher M1L WFA obtained through Delphi-MD, signifies better preservation and functional integrity of the motor network in patients with probable iNPH that had a sustained response to VPS than those that did not. Thus Delphi-MD shows promise as an objective, accurate, and accessible ancillary screening tool for iNPH candidates, prior to referral for VPS treatment.

Authors/Disclosures
Hilla Fogel, PhD
PRESENTER
Dr. Fogel has received personal compensation for serving as an employee of QuantalX Neuroscience. Dr. Fogel has received personal compensation in the range of $5,000-$9,999 for serving as an officer or member of the Board of Directors for QuantalX Neuroscience. Dr. Fogel has received intellectual property interests from a discovery or technology relating to health care.
Tal Davidy, MD (Tel hashomer) Dr. Davidy has nothing to disclose.
Alexandra Suminski (Sheba Medical Center) No disclosure on file
Jacob Zauberman, MD Dr. Zauberman has nothing to disclose.
Tsviya Fay-Karmon, MD No disclosure on file
Saar Anis, MD (Cleveland Clinic) Dr. Anis has nothing to disclose.
Hassin a. Adi Miss Adi has nothing to disclose.
Noa Zifman, MSc Mrs. Zifman has received personal compensation for serving as an employee of QuantalX Neuroscience Ltd.. Mrs. Zifman has received intellectual property interests from a discovery or technology relating to health care.
Orit H. Lesman-Segev, MD Dr. Lesman-Segev has nothing to disclose.
Sharon Hassin-Baer, MD (Chaim Sheba Medical Center) Dr. Hassin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ABBVIE. Dr. Hassin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MEDISON. Dr. Hassin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TEVA. Dr. Hassin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ABBVIE. Dr. Hassin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ABBVIE. Dr. Hassin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TEVA.